Andova, Sanela and Serafimovska, Tijana and Zdravkovska, Milka and Balkanov, Trajan and Darkovska-Serafimovska, Marija (2020) Pharmacotherapy approach in kidney cancer therapy. Knowledge - International Journal, Scientific Papers. ISSN 2545-4439
Preview |
Text
KIJ, Vol. 38.4.pdf Download (532kB) | Preview |
Abstract
Kidney cancer is a common cause of death for many patients worldwide.The exact cause of kidney cancer
is unknown. Factors that increase the risk of developing kidney cancer are: old age, chronic kidney failure, dialysis, polycystic kidney disease, kidney stones, etc. It’s targeting and elimination is still a problem in modern medicine. Chemotherapy, radiation, surgery, and immunotherapy ас standard treatments for this type of cancer do not give satisfactory results. One of the newer approaches in the treatment of kidney cancer is the use of tyrosine kinase inhibitors (sunitinib or pazopanib) that inhibit angiogenesis by preventing the growth, development and metastasis of cancer. Both medicines have inhibitory effects against vascular endothelial growth factor (VEGF) and inhibit its biological activities (blood vessel formation, cancer progression). More specifically, these drugs are tyrosine kinase inhibitors and inhibit the biochemical pathways that take place inside the cell when a ligand binds to the receptor.
Tyrosine kinase pathways stimulate angiogenesis in cancer cells, and thus promote cancer progression. Sunitinib and
pazopanib inhibit these intracellular pathways and lead to anticancer effects. The purpose of this study was to
evaluate available clinical trials of sunitinib and pazopanib as new targeted kidney cancer therapies, to evaluate the pharmacotherapeutic effect and side effects of sunitinib and pazopanib and to identify the strengths and weaknesses of the both medicines. In all clinical studies described in this thesis, it can be conclude that both medicines have an impact on overall survival without progression of disease and objective response rate. It can also be noted that sunitinib and pazopanib have better and more effective anticancer abilities compared to cytokine therapy. Which of these two medicines has better pharmacological effects cannot be said with certainty because most studies give different results. Some studies confirm a better effect of sunitinib, others on pazopanib, and some show that both medicines have the same or similar therapeutic response. One of the reasons for the contradictory results is that all clinical studies have been examined in different clinical centers around the world, involving patients of different
races. Both medicines are generally well tolerated by patients, but side effects of therapy are a accompanying
effects. The most common side effects are: hypertension, diarrhea, fatigue, nausea, vomiting, elevated serum levels of AST and ALT. It has been reported that the lack of pharmacogenetic and pharmacogenomic screening of patients prior to the administration of sunitinib and pazopanib leads to toxic effects or lack of therapeutic effects.
| Item Type: | Article |
|---|---|
| Impact Factor Value: | 1.822 |
| Subjects: | Medical and Health Sciences > Clinical medicine |
| Divisions: | Faculty of Medical Science |
| Depositing User: | Marija Darkovska-Serafimovska |
| Date Deposited: | 23 Apr 2020 13:44 |
| Last Modified: | 23 Apr 2020 13:44 |
| URI: | https://eprints.ugd.edu.mk/id/eprint/24009 |
Actions (login required)
 |
View Item |